- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04527874
Viral Load Triggered ART Care in Lesotho (VITAL)
Assessment of a Viral Load Result-driven Automated Differentiated Service Delivery Model for Participants Taking Antiretroviral Therapy in Lesotho
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To sustainably provide good quality care to increasing numbers of people living with HIV (PLHIV) receiving antiretroviral therapy (ART), care delivery has to shift from a "one-size-fits-all" approach to differentiated care models. Such models should reallocate resources from patients who are doing well to patient groups who may need more attention, such as those with treatment failure or medical and psycho-social problems. Ideally, such a reallocation allows health systems and patients to save resources while improving quality of care.
One proposed approach to differentiate care and intensity of monitoring is viral load-driven differentiated service delivery. Reducing the intensity of monitoring in patients with suppressed viral load (VL) and no other clinical problems would substantially reduce the workload at health care facilities and save time and transport cost for patients, thus potentially improve long-term engagement in care. Time and resources saved in patients with suppressed VL and no other clinical problems would allow focusing on those participants with elevated viral load and/or other clinical problems (like tuberculosis, which is the most common cause of mortality among PLHIV in sub-Saharan Africa). This may potentially improve PLHIVs' clinical outcome through intensified adherence support, clinical follow-up and timely switches to second-line ART. In many settings in sub-Saharan Africa, however, the potential of VL monitoring to differentiate care is not exploited and thus constitutes a missed opportunity. In Lesotho it was shown that the majority of unsuppressed VLs are not acted upon in a timely manner, be it due to providers and patients not being aware of the results or health care providers not being proficient in the management of treatment failure.
The concept of the proposed automated differentiated service delivery model (aDSDM) is to use VL results, other clinical characteristics (TB screening results and CD4 cell counts) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically capitalising on an existing VL database platform. The implemented aDSDM will differentiate care according to three elements:
- clinical characteristics (with focus on VL measurement)
- sub-population (women, men)
- participants' and health care providers' preferences
To ensure effective flow of information, VL results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening. The proposed aDSDM is designed for being scaled up at national and regional level as it mainly builds on automated triage and communication with participants and health care workers, thus not requiring additional human resources.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Butha-Buthe, Lesotho
- Muela Health Center
-
Butha-Buthe, Lesotho
- St. Peters Health Center
-
Butha-Buthe, Lesotho
- Boiketsiso Health Center
-
Butha-Buthe, Lesotho
- Linakeng Health Center
-
Butha-Buthe, Lesotho
- Makhunoane Health Center
-
Butha-Buthe, Lesotho
- Motete Health Center
-
Butha-Buthe, Lesotho
- Ngoajane Health Center
-
Butha-Buthe, Lesotho
- Rampai Health Center
-
Butha-Buthe, Lesotho
- St Paul Health Center
-
Butha-Buthe, Lesotho
- Tsime Health Center
-
Mokhotlong, Lesotho
- Libibing
-
Mokhotlong, Lesotho
- Linakaneng health center
-
Mokhotlong, Lesotho
- Malefiloane health center
-
Mokhotlong, Lesotho
- Mapholaneng
-
Mokhotlong, Lesotho
- Moeketsane
-
Mokhotlong, Lesotho
- Molikaliko health center
-
Mokhotlong, Lesotho
- St. James
-
Mokhotlong, Lesotho
- St. Martins
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
On an individual level, the inclusion criteria for the VITAL trial are the following:
- Taking antiretroviral therapy (independent of viral suppression)
- ≥ 18 years old
- Written informed consent
- intention to remain in the same facility for the duration of the trial
- not enrolled in another study if judged as non-compatible by the (Local) Principal Investigator
On a cluster level, inclusion criteria for the VITAL trial are the following:
- nurse-led public or missionary clinic in the districts of Butha-Buthe and Mokhotlong
- consent of clinic management (signed agreement with clinic management)
- access to the internet (internet connection must not be constant, but there must be possibility to down- and upload information daily)
- the clinic sends VL samples to Butha-Buthe laboratory for analysis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Intervention
Clusters in the intervention arm receive the VITAL intervention (see intervention)
|
The concept of the VITAL, an automated differentiated service delivery model (aDSDM), is to use viral load results, other clinical characteristics (TB screening results and CD4 cell counts, comorbidities) and participants' preference to automatically triage participants into groups requiring different levels of attention and care. Innovatively, triaging of participants will be done automatically making use of a dedicated mobile App and a viral load database platform. To ensure effective flow of information and empowerment of patients, viral load results and other relevant information is sent directly to participants' phones, whereas health care providers receive results directly on their study tablet together with the recommended action. Further features of the platform are preference-based tailored adherence reminders and automated calls to participants for symptomatic tuberculosis screening.
Other Names:
|
No Intervention: Control
Clusters in the control arm continue standard of care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Engagement in care with documented viral suppression
Time Frame: 16-28 months after enrollment
|
Proportion of participants engaged in care (defined as documented visit attendance) with documented viral suppression (<20 copies/mL) 24 months (16-28 months) after enrollment
|
16-28 months after enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Viral re-suppression
Time Frame: 16-28 months after enrollment
|
Proportion of participants with viral re-suppression (<20 copies/mL) 24 months (16-28 months) after enrollment among all participants with an unsuppressed VL (≥ 20 copies/mL) during the first 12 months of follow-up
|
16-28 months after enrollment
|
Sustained viral suppression
Time Frame: 16-28 months after enrollment
|
Proportion of participants with sustained viral suppression (defined as >1 VL <20 copies/mL) during 24 months (16-28 months) follow-up
|
16-28 months after enrollment
|
Mortality rate
Time Frame: at 12 and 24 months after enrollment
|
at 12 and 24 months after enrollment
|
|
Proportion of participants with confirmed TB diagnosis
Time Frame: at 12 and 24 months after enrollment
|
at 12 and 24 months after enrollment
|
|
Disengagement from care
Time Frame: at 12 and 24 months after enrollment
|
Proportion of participants disengaged from care (defined as no documented visit attendance) at 12 months (8-16 months) and 24 months (16-28 months) after enrollment
|
at 12 and 24 months after enrollment
|
Time to follow-up viral load in case of an unsuppressed VL (≥ 20 copies/mL)
Time Frame: at 24 months after enrollment
|
at 24 months after enrollment
|
|
Time to switch of ART regimen in case of virologic failure
Time Frame: at 24 months after enrollment
|
at 24 months after enrollment
|
|
Rate of clinic visits
Time Frame: at 24 months after enrollment
|
at 24 months after enrollment
|
|
Proportion of participants switched to second-line ART
Time Frame: at 12 and 24 months after enrollment
|
Proportion of participants switched to second-line ART at 12 and 24 months among participants with virologic failure
|
at 12 and 24 months after enrollment
|
Proportion of participants diagnosed with TB
Time Frame: at 12 and 24 months after enrollment
|
at 12 and 24 months after enrollment
|
|
Proportion of participants receiving a course of TPT
Time Frame: at 24 months after enrollment
|
at 24 months after enrollment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of participants requesting a VL result notification through SMS
Time Frame: at 24 months after enrollment
|
in intervention clusters
|
at 24 months after enrollment
|
Proportion of SMS delivered successfully
Time Frame: at 24 months after enrollment
|
in intervention clusters
|
at 24 months after enrollment
|
Proportion of participants using the call-back option through District ART Nurse
Time Frame: at 24 months after enrollment
|
in intervention clusters
|
at 24 months after enrollment
|
Proportion of participants screened positive fo TB by automated call
Time Frame: at 24 months after enrollment
|
in intervention clusters
|
at 24 months after enrollment
|
Proportion of participants appreciating the automated differentiated service deliver model
Time Frame: at 24 months after enrollment
|
in intervention clusters
|
at 24 months after enrollment
|
Proportion of health care providers appreciating the automated differentiated service delivery model
Time Frame: at 24 months after enrollment
|
in intervention clusters
|
at 24 months after enrollment
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Urogenital Diseases
- Genital Diseases
- HIV Infections
Other Study ID Numbers
- P002-20-1.0
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on VITAL model
-
Hamilton Health Sciences CorporationMcMaster University; Population Health Research Institute; Cloud DX Inc.Not yet recruitingBlood Pressure | Respiration | Temperature | Heart Rate | Oxygen Saturation | Pulse RateCanada
-
Bio-Medical Research, Ltd.Completed
-
Atlantic TherapeuticsCompletedStress Urinary IncontinenceGermany
-
Bio-Medical Research, Ltd.CompletedHealthy Female VolunteersUnited States
-
Uşak UniversityRecruitingPulpitis | Post Operative Pain | ToothacheTurkey
-
Military Institute of Medicine, PolandWroclaw Medical University; Medical University of Gdansk; 4th Military Hospital; Military University of TechnologyCompleted
-
Cambridge University Hospitals NHS Foundation TrustUniversity of CambridgeRecruitingPreterm Infant | Low; Birthweight, Extremely (999 Grams or Less) | Infant, NewbornUnited Kingdom
-
The Cleveland ClinicNot yet recruiting
-
Sciema UGCompletedDiabetes MellitusGermany
-
Mexican Red CrossInstituto Bioclon S.A. de C.V.Completed